Registration Dossier
Registration Dossier
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 205-087-0 | CAS number: 133-06-2
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data

Repeated dose toxicity: oral
Administrative data
- Endpoint:
- chronic toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 24 October 1986 to 3 December 1987
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 1 988
- Report date:
- 1988
Materials and methods
Test guideline
- Qualifier:
- according to guideline
- Guideline:
- EPA OPP 83-1 (Chronic Toxicity)
- Deviations:
- no
- GLP compliance:
- yes
- Limit test:
- yes
Test material
- Reference substance name:
- Captan
- EC Number:
- 205-087-0
- EC Name:
- Captan
- Cas Number:
- 133-06-2
- Molecular formula:
- C9H8Cl3NO2S
- IUPAC Name:
- 2-[(trichloromethyl)sulfanyl]-2,3,3a,4,7,7a-hexahydro-1H-isoindole-1,3-dione
- Test material form:
- solid: particulate/powder
- Details on test material:
- - Name of test material: Captan Technical, N-(trichloromethylthio)cyclohex-4-ene-1,2-dicarboximide
- Molecular formula: C9H8Cl3NO2S
- Molecular mass: 300.59
- Physical state: white powder
- Analytical purity: 90.4 % (w/w)
- Batch number: WRC 4921-26-15
- Date of arrival: 7 July 1986
- Storage conditions: room temperature
This sample of Captan Technical was assayed before the study began and was found to contain 90.4 wt. % captan. Retain samples analyzed 35-months later assayed at 89.0 and 88.8 wt.% captan, thus demonstrating the stability of the test material through the duration of the 12-month chronic toxicity study.
Constituent 1
Test animals
- Species:
- dog
- Strain:
- Beagle
- Sex:
- male/female
Administration / exposure
- Route of administration:
- oral: capsule
- Vehicle:
- unchanged (no vehicle)
- Analytical verification of doses or concentrations:
- yes
- Duration of treatment / exposure:
- 52 weeks (one year)
- Frequency of treatment:
- once/day
Doses / concentrationsopen allclose all
- Dose / conc.:
- 12.5 mg/kg bw/day (actual dose received)
- Dose / conc.:
- 60 mg/kg bw/day (actual dose received)
- Dose / conc.:
- 300 mg/kg bw/day (actual dose received)
- No. of animals per sex per dose:
- Three groups: 12.5, 60 and 300 mg/kg bw/day (5/sex/dose). Control group: empty gelatine capsules (5/sex).
- Control animals:
- yes, concurrent no treatment
Examinations
- Observations and examinations performed and frequency:
- CAGE SIDE OBSERVATIONS: Yes
DETAILED CLINICAL OBSERVATIONS: Yes
BODY WEIGHT: Yes
FOOD EFFICIENCY:
- Body weight gain in kg/food consumption in kg per unit time X 100 calculated as time-weighted averages from the consumption and body weight gain data: Yes
OPHTHALMOSCOPIC EXAMINATION: Yes
HAEMATOLOGY: Yes
CLINICAL CHEMISTRY: Yes
URINALYSIS: Yes - Sacrifice and pathology:
- GROSS PATHOLOGY: Yes
HISTOPATHOLOGY: Yes
Results and discussion
Results of examinations
- Clinical signs:
- no effects observed
- Mortality:
- no mortality observed
- Body weight and weight changes:
- no effects observed
- Food consumption and compound intake (if feeding study):
- no effects observed
- Food efficiency:
- no effects observed
- Ophthalmological findings:
- no effects observed
- Haematological findings:
- no effects observed
- Clinical biochemistry findings:
- no effects observed
- Urinalysis findings:
- no effects observed
- Behaviour (functional findings):
- no effects observed
- Organ weight findings including organ / body weight ratios:
- no effects observed
- Gross pathological findings:
- no effects observed
- Histopathological findings: non-neoplastic:
- no effects observed
- Histopathological findings: neoplastic:
- no effects observed
Effect levels
- Key result
- Dose descriptor:
- NOEL
- Effect level:
- 300 mg/kg bw/day (actual dose received)
- Based on:
- act. ingr.
- Sex:
- male/female
- Basis for effect level:
- other: Captan Technical was well tolerated by dogs when administered orally in gelatin capsules at dose levels up to 300 mg/kg/day for 52 weeks.
Target system / organ toxicity
- Critical effects observed:
- not specified
Any other information on results incl. tables
Captan Technical was administered orally by capsule to beagle dogs at dosage levels of 12.5, 60.0 and 300.0 mg/kg/day for 52 weeks. Control dogs received empty gelatin capsules. Five male and five female animals were initiated on study in each of the four groups.
All animals survived until the termination of the study. The 300 mg/kg/day dosage level had a higher incidence of emesis and soft/mucoid stool compared to those of the control group. These observations were considered to be related to administration of the test substance.
One female at the 60 mg/kg/day dosage was noted with observation "appears to have convulsed" on three days during the study. Convulsions have been observed spontaneously in dogs at IRDC although at a low incidence. Microscopically all tissues for this animal were within normal limits. Since the finding was observed rarely, and only in one mid-dose animal, it was not considered to be related to administration of the test article.
General observations: There were no mortalities during the study. A higher incidence of emesis and soft/mucoid stool was sporadically noted in 300 mg/kg bw/day animals compared to the control, although these were also noted in other groups including controls. This was probably a treatment-related effect but was not considered as a toxicological effect.
There were no significant differences in group mean body weight at any interval. Food consumption values for females administered test substance appeared lower than control females. However, food consumption in the control group females was considered higher than normal and therefore no toxicological significance is attached to the relatively low food consumption in the 60 and 300 mg/kg bw/day animals. No treatment-related
ophthalmological abnormalities were detected. Physical examination findings revealed no significant findings.
Haematology, clinical chemistry and urinalysis: There were no treatment-related effects on haematological or clinical chemistry parameters and urinalysis was considered normal.
Gross pathology, organ weights and histopathology: No treatment-related gross pathological changes were observed. Absolute organ weights were unaffected by treatment. A significant increase in the liver weight was observed in 300 mg/kg bw/day males compared to the control. This was considered to be related to the lower body weight observed in this group compared to the control and not treatment-related. No treatment-related histopathological changes were observed.
Table 7.5.1-1: Group mean body weight at study week 52 and the percent differences from the pretest
Dosage Level (mg/kg/day) | Mean Body Weights, kg, Week 52 (percent difference from pretest) | |||||
Male | Female | |||||
Pretest | Week 52 | % difference | Pretest | Week 52 | % difference | |
0.0 | 12.2 | 13.3 | +9.0 | 9.0 | 9.4 | +4.4 |
12.5 | 11.7 | 12.9 | +10.3 | 9.3 | 10.1 | +8.6 |
60.0 | 11.1 | 11.8 | +6.3 | 9.3 | 10.8 | +16.1 |
300 | 11.7 | 12.6 | +7.7 | 9.4 | 10.00 | +6.4 |
Table 7.5.1-2: Average group mean food consumption g/animal/day for study weeks 1 through 52 and the percent difference from the control group
Dosage Level (mg/kg/day) | Average Group Mean Food Consumption, g/animal/day (percent difference from control) | |||
Male | Female | |||
| % difference |
| % difference | |
0.0 | 389 |
| 408 |
|
12.5 | 417 | +7.2 | 311 | -23.8 |
60.0 | 441 | +13.4 | 316 | -22.5 |
300.0 | 413 | +6.2 | 351 | -14.0 |
Table 7.5.1-3-: Average group mean food consumption g/kg/day for study weeks 1 through 52 and the percent difference from the control group
Dosage Level (mg/kg/day) | Average Group Mean Food Consumption, g/kg/day (percent difference from control) | |||
Male | Female | |||
| % difference |
| % difference | |
0.0 | 30.1 |
| 44.4 |
|
12.5 | 33.8 | + 12.3 | 31.5 | -29.1 |
60.0 | 38.0 | +26.2 | 32.1 | -27.7 |
300.0 | 34.5 | +14.6 | 36.5 | -17.8 |
Applicant's summary and conclusion
- Conclusions:
- The NOEL was 300 mg/kg bw/day in both male and female dogs.
- Executive summary:
Captan Technical was administered orally by capsule to beagle dogs at dosage levels of 12.5, 60.0 and 300.0 mg/kg/day for 52 weeks; control dogs received empty gelatin capsules. The dose levels for this study were selected on the basis of a preliminary four week range finding study in dogs in which dose levels of 300 mg/kg/day and above produced emesis, in appetence and a reduction in body weight.
Computerized random selection in a block design based on body weights. Animals with large absolute differences from the quarantine population body weight mean eliminated prior to randomization and homogeneity of group body weight variances used as the criteria for acceptance. Body weights, food consumption values, clinical pathology parameters and organ weight values analyzed using analysis of variance and Bartlett's test. Treatment groups compared to the control group, by sex, using the appropriate t-statistic (equal or unequal variance). Nonparametric analysis, when appropriate, by rank transformation.
Observations noted for dogs in the 12.5 mg/kg/day group were similar to those recorded for the control group. Body weight gains were similar in all groups. Food consumption values in male groups were comparable through the study. Food consumption values in female dogs administered the test substance appeared to be less than those for control females. However, food consumption values for the female control group were higher than normal. Food consumption for all female dogs exposed to the test substance was considered normal at around 300 to 350 g/dog/day. Consequently no toxicological significance was attributed to the apparent reduction in food consumption in test substance treated animals.
Other observations and examinations performed during the in-life phase of the study were unremarkable. No test substance related abnormalities were detected during the ophthalmoscopic examinations, detailed physical examinations, and the clinical pathology evaluations.
No test article related macroscopic changes were observed in any of the male or female dogs that were terminally sacrificed after a one year period of study. Occasional changes that were seen at necropsy in these dogs were considered incidental in nature and unrelated to the administration of the test article.
At terminal sacrifice, no test article related organ weight changes were observed in any of the treatment groups.
There were no test article related microscopic changes in any of the male or female dogs that were sacrificed after a one year period of study. Occasional changes were seen in a variety of organs, but these were considered spontaneous in nature and usual for dogs of this age and breed.
In conclusion Captan Technical was well tolerated by dogs when administered orally in gelatin capsules at dosage levels up to 300 mg/kg/day for 52 weeks. There was some emesis and soft/mucoid stool at the 300 mg/kg/day level. However, these signs were regarded as a response to the taste and physical nature of the test substance rather than a toxicological effect. The no toxic effect dose level in this study was 300 mg of Captan Technical/kg/day to both male and female dogs. Daily dosage of higher than 300 mg/kg was considered likely to result in significant toxicity and potentially lead to deaths in a one year study.
The NOEL for oral administration of captan is set to 300 mg/kg bw/day in both male and female dogs.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.

EU Privacy Disclaimer
Sellel veebilehel kasutatakse küpsiseid, et tagada lehe parim kasutus.